Last reviewed · How we verify
GMA301 Injection
At a glance
| Generic name | GMA301 Injection |
|---|---|
| Sponsor | Gmax Biopharm Australia Pty Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension (PHASE1)
- A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GMA301 Injection CI brief — competitive landscape report
- GMA301 Injection updates RSS · CI watch RSS
- Gmax Biopharm Australia Pty Ltd. portfolio CI